EZH2 and colorectal cancer: Silencing of ST6GalNAc6 is induced by the NF-κB-mediated YY1/PRC2/EZH2 axis, which binds to its promoter and represses activity, leading to loss of immunosuppression and promotion of colorectal cancer progression [151].